Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ligustrazine phosphate (also known as tetramethylpyrazine phosphate) is a small molecule synthetic derivative of ligustrazine, an active compound originally extracted from the traditional Chinese medicinal herb *Rhizoma Chuanxiong* (Szechuan lovage). Developed and manufactured by Hainan Shuangcheng Pharmaceuticals as an injectable formulation, it primarily functions as a calcium antagonist. The drug exhibits potent vasodilatory, neuroprotective, and antiplatelet aggregation effects, which facilitate the expansion of small arteries, improvement of microcirculation, and enhancement of cerebral blood flow. It is clinically approved in China for the treatment of several conditions, including ischemic stroke, coronary heart disease, diabetic nephropathy, and knee osteoarthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ligustrazine phosphate.